A note out of the Macquarie equities desk reveals that its analysts have upgraded this healthcare company’s shares to an outperform rating with an improved price target of $3.00. Macquarie believes that Healius won’t be impacted by the pandemic as much as previously expected. It also feels the company is well-placed to benefit from an increase in activity in the near term. In addition to this, it appears to see the potential divestment of its medical centres as a positive
Ann: Trading update, page-70
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add HLS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.72 |
Change
0.010(0.58%) |
Mkt cap ! $1.248B | |||
| Open | High | Low | Value | Volume |
| $1.71 | $1.73 | $1.69 | $1.642M | 958.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2230 | $1.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.73 | 4762 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| HLS (ASX) Chart |